BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 31465302)

  • 1. Resident memory CD8+ T cells within cancer islands mediate survival in breast cancer patients.
    Egelston CA; Avalos C; Tu TY; Rosario A; Wang R; Solomon S; Srinivasan G; Nelson MS; Huang Y; Lim MH; Simons DL; He TF; Yim JH; Kruper L; Mortimer J; Yost S; Guo W; Ruel C; Frankel PH; Yuan Y; Lee PP
    JCI Insight; 2019 Oct; 4(19):. PubMed ID: 31465302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional Heterogeneity of CD4
    Oja AE; Piet B; van der Zwan D; Blaauwgeers H; Mensink M; de Kivit S; Borst J; Nolte MA; van Lier RAW; Stark R; Hombrink P
    Front Immunol; 2018; 9():2654. PubMed ID: 30505306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer.
    Webb JR; Milne K; Watson P; Deleeuw RJ; Nelson BH
    Clin Cancer Res; 2014 Jan; 20(2):434-44. PubMed ID: 24190978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD8+CD103+ tissue-resident memory T cells convey reduced protective immunity in cutaneous squamous cell carcinoma.
    Lai C; Coltart G; Shapanis A; Healy C; Alabdulkareem A; Selvendran S; Theaker J; Sommerlad M; Rose-Zerilli M; Al-Shamkhani A; Healy E
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Emerging Role of CD8
    Corgnac S; Boutet M; Kfoury M; Naltet C; Mami-Chouaib F
    Front Immunol; 2018; 9():1904. PubMed ID: 30158938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD103 and Intratumoral Immune Response in Breast Cancer.
    Wang ZQ; Milne K; Derocher H; Webb JR; Nelson BH; Watson PH
    Clin Cancer Res; 2016 Dec; 22(24):6290-6297. PubMed ID: 27267849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of tumor-infiltrating CD103 resident memory T-cell content in recurrent laryngeal squamous cell carcinoma.
    Mann JE; Smith JD; Birkeland AC; Bellile E; Swiecicki P; Mierzwa M; Chinn SB; Shuman AG; Malloy KM; Casper KA; McLean SA; Moyer JS; Wolf GT; Bradford CR; Prince ME; Carey TE; McHugh JB; Spector ME; Brenner JC
    Cancer Immunol Immunother; 2019 Feb; 68(2):213-220. PubMed ID: 30361882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of CD103
    Han L; Gao QL; Zhou XM; Shi C; Chen GY; Song YP; Yao YJ; Zhao YM; Wen XY; Liu SL; Qi YM; Gao YF
    Cancer Immunol Immunother; 2020 Aug; 69(8):1493-1504. PubMed ID: 32285170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Morphological Evaluation of Tumor-Infiltrating Lymphocytes (TILs) to Investigate Invasive Breast Cancer Immunogenicity, Reveal Lymphocytic Networks and Help Relapse Prediction: A Retrospective Study.
    Romagnoli G; Wiedermann M; Hübner F; Wenners A; Mathiak M; Röcken C; Maass N; Klapper W; Alkatout I
    Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28885584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paxillin Binding to the Cytoplasmic Domain of CD103 Promotes Cell Adhesion and Effector Functions for CD8
    Gauthier L; Corgnac S; Boutet M; Gros G; Validire P; Bismuth G; Mami-Chouaib F
    Cancer Res; 2017 Dec; 77(24):7072-7082. PubMed ID: 29021139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distribution, phenotype, functional and clinical relevance of CD8
    Shen Y; Li XL; Li YX; Shan ZG; Zhao YL; Cheng P; Zhao Z; Zhang JY; Chen W; Zhuang Y; Ma DY; Zou QM; Qiu Y; Peng LS
    Cancer Immunol Immunother; 2022 Jul; 71(7):1645-1654. PubMed ID: 34767045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-1 and CD103 Are Widely Coexpressed on Prognostically Favorable Intraepithelial CD8 T Cells in Human Ovarian Cancer.
    Webb JR; Milne K; Nelson BH
    Cancer Immunol Res; 2015 Aug; 3(8):926-35. PubMed ID: 25957117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD103
    Xiao Y; Li H; Mao L; Yang QC; Fu LQ; Wu CC; Liu B; Sun ZJ
    J Dent Res; 2019 Dec; 98(13):1480-1487. PubMed ID: 31658426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD103+ Tumor Infiltrating Lymphocytes Predict a Favorable Prognosis in Urothelial Cell Carcinoma of the Bladder.
    Wang B; Wu S; Zeng H; Liu Z; Dong W; He W; Chen X; Dong X; Zheng L; Lin T; Huang J
    J Urol; 2015 Aug; 194(2):556-62. PubMed ID: 25752441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined evaluation of the FAS cell surface death receptor and CD8+ tumor infiltrating lymphocytes as a prognostic biomarker in breast cancer.
    Blok EJ; van den Bulk J; Dekker-Ensink NG; Derr R; Kanters C; Bastiaannet E; Kroep JR; van de Velde CJ; Kuppen PJ
    Oncotarget; 2017 Feb; 8(9):15610-15620. PubMed ID: 28121628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD103
    Wang P; Huang B; Gao Y; Yang J; Liang Z; Zhang N; Fu X; Li L
    Cell Immunol; 2018 Mar; 325():48-55. PubMed ID: 29448979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fatty Acid Oxidation Controls CD8
    Lin R; Zhang H; Yuan Y; He Q; Zhou J; Li S; Sun Y; Li DY; Qiu HB; Wang W; Zhuang Z; Chen B; Huang Y; Liu C; Wang Y; Cai S; Ke Z; He W
    Cancer Immunol Res; 2020 Apr; 8(4):479-492. PubMed ID: 32075801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD103 defines intraepithelial CD8+ PD1+ tumour-infiltrating lymphocytes of prognostic significance in endometrial adenocarcinoma.
    Workel HH; Komdeur FL; Wouters MC; Plat A; Klip HG; Eggink FA; Wisman GB; Arts HJ; Oonk MH; Mourits MJ; Yigit R; Versluis M; Duiker EW; Hollema H; de Bruyn M; Nijman HW
    Eur J Cancer; 2016 Jun; 60():1-11. PubMed ID: 27038842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tertiary lymphoid structures show infiltration of effective tumor-resident T cells in gastric cancer.
    Mori T; Tanaka H; Suzuki S; Deguchi S; Yamakoshi Y; Yoshii M; Miki Y; Tamura T; Toyokawa T; Lee S; Muguruma K; Wanibuchi H; Ohira M
    Cancer Sci; 2021 May; 112(5):1746-1757. PubMed ID: 33735485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined Immunoscore of CD103 and CD3 Identifies Long-Term Survivors in High-Grade Serous Ovarian Cancer.
    Bösmüller HC; Wagner P; Peper JK; Schuster H; Pham DL; Greif K; Beschorner C; Rammensee HG; Stevanović S; Fend F; Staebler A
    Int J Gynecol Cancer; 2016 May; 26(4):671-9. PubMed ID: 26905331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.